Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences (NASDAQ:GILD), shares in AbbVie, Inc (NYSE:ABBV) tumbled by 12.8% last month.

AbbVie is under pressure to overcome looming headwinds tied to the fast-approaching patent expiration on its top selling drug, Humira, but its unclear whether its efforts will succeed. In the following slideshow, I highlight the risks to AbbVie and how it hopes to overcome them. 


Why AbbVie Slumped 13% In September from The Motley Fool